Frontpage Hero

Because we care, we need to act

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.

Annual General Meeting 2018

The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2017 publicly available*. This includes sponsorships to attend meetings, grants and donations,...

05/31/2018 - 14:00

Recent data show quality-of-life improvements for patients treated prophylactically with Elocta® and Alprolix®, extended half-life haemophilia therapies.

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) will present data at the World Federation of Hemophilia (WFH)...

05/21/2018 - 07:00

The Sobi AGM was convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability

The AGM adopted the income statements and the balance...

05/09/2018 - 17:30

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the first quarter 2018. Total revenues grew 41 per cent compared to Q1 2017 and amounted to SEK 1,964 M. EBITA was SEK 771 M, an increase of 90 per cent and gross margin amounted to 72 per cent...

04/26/2018 - 08:00
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden